DE2352662A1 - Verfahren zur herstellung eines uebertragungsfaktors - Google Patents
Verfahren zur herstellung eines uebertragungsfaktorsInfo
- Publication number
- DE2352662A1 DE2352662A1 DE19732352662 DE2352662A DE2352662A1 DE 2352662 A1 DE2352662 A1 DE 2352662A1 DE 19732352662 DE19732352662 DE 19732352662 DE 2352662 A DE2352662 A DE 2352662A DE 2352662 A1 DE2352662 A1 DE 2352662A1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- transfer factor
- transfer
- factor
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010074506 Transfer Factor Proteins 0.000 title claims description 59
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 210000004027 cell Anatomy 0.000 claims description 67
- 210000004698 lymphocyte Anatomy 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 31
- 230000005540 biological transmission Effects 0.000 claims description 25
- 238000000605 extraction Methods 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 239000000427 antigen Substances 0.000 description 25
- 102000036639 antigens Human genes 0.000 description 25
- 108091007433 antigens Proteins 0.000 description 25
- 238000012546 transfer Methods 0.000 description 22
- 239000000126 substance Substances 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 10
- 230000007969 cellular immunity Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 241000282520 Papio Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000012364 cultivation method Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 201000006082 Chickenpox Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010056332 Panencephalitis Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010021432 Immunisation reaction Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010042938 Systemic candida Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 208000003669 immune deficiency disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001100 mitostatic effect Effects 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical class 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB4848672A GB1443948A (en) | 1972-10-20 | 1972-10-20 | Production of immunological material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2352662A1 true DE2352662A1 (de) | 1974-05-02 |
Family
ID=10448800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19732352662 Ceased DE2352662A1 (de) | 1972-10-20 | 1973-10-19 | Verfahren zur herstellung eines uebertragungsfaktors |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS4993523A (enExample) |
| AT (1) | AT330349B (enExample) |
| BE (1) | BE806251A (enExample) |
| CA (1) | CA996481A (enExample) |
| CH (1) | CH581196A5 (enExample) |
| DE (1) | DE2352662A1 (enExample) |
| FR (1) | FR2203622B1 (enExample) |
| GB (1) | GB1443948A (enExample) |
| IE (1) | IE39141B1 (enExample) |
| IL (1) | IL43453A (enExample) |
| NL (1) | NL7314505A (enExample) |
| SE (1) | SE416820B (enExample) |
| ZA (1) | ZA738085B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0041189A1 (de) * | 1980-05-22 | 1981-12-09 | Stiftung Deutsches Krebsforschungszentrum | Verfahren zur Herstellung von Interferon II und stimulierte Klone zur Durchführung des Verfahrens |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1594097A (en) | 1976-12-16 | 1981-07-30 | Int Inst Of Differentiation | Production of specific immune nucleic acids cell dialysates and antibodies |
| GB2156214B (en) * | 1982-04-30 | 1988-05-25 | Viragen Inc | Topical transfer factor compositions |
| JPS6028935A (ja) * | 1983-07-25 | 1985-02-14 | Hamamatsu Ika Daigaku | 新規ヒト抗体産生増強因子およびその製造法 |
| US4572834A (en) * | 1984-04-10 | 1986-02-25 | Clinical Reference Laboratory, Inc. | Biologic and method of preparing same |
| JPS6124520A (ja) * | 1984-07-12 | 1986-02-03 | Takeshi Makitsubo | 腫瘍壊死因子様物質を抽出する方法 |
| JPS6156131A (ja) * | 1984-07-17 | 1986-03-20 | Takeshi Makitsubo | 腫瘍壊死因子様物質 |
| GB8614733D0 (en) * | 1986-06-17 | 1986-07-23 | Lefesvre A | Aids treatment |
| RU2624504C1 (ru) * | 2015-12-30 | 2017-07-04 | Маргарита Евгеньевна Дмитриева | Способ получения трансфер-фактора для профилактики вирусных болезней птиц |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2088229A1 (en) * | 1970-05-29 | 1972-01-07 | Anvar | Medicaments contg cellular rna - formation of interferon and treatment of viral infections |
-
1972
- 1972-10-20 GB GB4848672A patent/GB1443948A/en not_active Expired
-
1973
- 1973-10-16 FR FR7336814A patent/FR2203622B1/fr not_active Expired
- 1973-10-18 BE BE136841A patent/BE806251A/xx unknown
- 1973-10-18 ZA ZA738085A patent/ZA738085B/xx unknown
- 1973-10-19 SE SE7314239A patent/SE416820B/xx unknown
- 1973-10-19 CH CH1483673A patent/CH581196A5/xx not_active IP Right Cessation
- 1973-10-19 JP JP48117688A patent/JPS4993523A/ja active Pending
- 1973-10-19 DE DE19732352662 patent/DE2352662A1/de not_active Ceased
- 1973-10-19 AT AT887873A patent/AT330349B/de not_active IP Right Cessation
- 1973-10-21 IL IL43453A patent/IL43453A/en unknown
- 1973-10-22 CA CA183,943A patent/CA996481A/fr not_active Expired
- 1973-10-22 IE IE1887/73A patent/IE39141B1/xx unknown
- 1973-10-22 NL NL7314505A patent/NL7314505A/xx not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0041189A1 (de) * | 1980-05-22 | 1981-12-09 | Stiftung Deutsches Krebsforschungszentrum | Verfahren zur Herstellung von Interferon II und stimulierte Klone zur Durchführung des Verfahrens |
Also Published As
| Publication number | Publication date |
|---|---|
| IE39141L (en) | 1974-04-20 |
| FR2203622B1 (enExample) | 1977-11-04 |
| ZA738085B (en) | 1974-10-30 |
| IE39141B1 (en) | 1978-08-16 |
| CA996481A (fr) | 1976-09-07 |
| AU6166873A (en) | 1975-04-24 |
| SE416820B (sv) | 1981-02-09 |
| FR2203622A1 (enExample) | 1974-05-17 |
| NL7314505A (enExample) | 1974-04-23 |
| BE806251A (fr) | 1974-02-15 |
| AT330349B (de) | 1976-06-25 |
| JPS4993523A (enExample) | 1974-09-05 |
| GB1443948A (en) | 1976-07-28 |
| CH581196A5 (enExample) | 1976-10-29 |
| IL43453A0 (en) | 1974-01-14 |
| ATA887873A (de) | 1975-09-15 |
| IL43453A (en) | 1976-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3227262C3 (de) | Verfahren zur Herstellung von menschlichem Tumor-Nekrose-Faktor und menschlicher Tumor-Nekrose-Faktor | |
| DE2902136C2 (de) | Verfahren zum Herstellen von Interferon | |
| DE3001585A1 (de) | Verfahren zur herstellung von interferon typ ii und es enthaltende zubereitungen | |
| EP0584715B1 (de) | Verfahren zur Isolierung und Kultivierung von transformierten Zellen sowie Verwendung dieser Zellen zur Herstellung individuumsspezifischer Antikörper | |
| DE2314076C3 (de) | Verfahren zur Herstellung von karzinoembyonischem Antigen | |
| CH629533A5 (de) | Verfahren zur gewinnung von insulin mittels genetisch umgebildeter funguszellen. | |
| DE2352662A1 (de) | Verfahren zur herstellung eines uebertragungsfaktors | |
| DE1949195A1 (de) | Verfahren zur Herstellung deproteinisierter Bluextrakte mit Heilwirkung | |
| DE1617397A1 (de) | Verfahren zur Herstellung eines tumorstatisch wirkenden Mittels | |
| DE2043971C3 (de) | Antitumorsubstanz aus haemolytischen Streptococcen | |
| AT395017B (de) | Verfahren zur herstellung eines neuen lymphokins (lk 2) sowie verwendung von lk 2 zur herstellung eines pharmazeutischen praeparates | |
| CH650154A5 (de) | Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung. | |
| DE2420415A1 (de) | Eine mitogenische blutfraktion und verfahren zur herstellung derselben | |
| DE841333C (de) | Verfahren zur Herstellung von Bakterienpraeparaten von Treponema Pallidum | |
| DE2819110C2 (de) | Verfahren zur Synthese von biologischen Peptidwirkstoffen | |
| DE2034118A1 (en) | Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins | |
| DE69013002T2 (de) | Uv-induzierter faktor für immununterdrückung. | |
| DE3913438A1 (de) | Verfahren zum herstellen einer immunitaetsgedaechtniszellsuspension | |
| DE3235913C2 (de) | Verfahren zur Gewinnung eines Krankheitskontrollprodukts | |
| DE3877102T2 (de) | Methode fuer die behandlung von viraler gehirnentzuendung. | |
| DE397551C (de) | Verfahren zur Gewinnung spezifischer Impfstoffe | |
| DE434751C (de) | Verfahren zur Herstellung von Antigonorrhoe-Frischvakzinen | |
| DE2162013C3 (de) | Tollwut-Lebendimpfstoff, Verfahren zu seiner Herstellung nd seine Verwendung bei der Bekämpfung von Tollwut | |
| DE590908C (de) | Verfahren zur Herstellung eines Scharlachserums | |
| DE2719547A1 (de) | Immunostimulin, verfahren zu dessen herstellung und seine verwendung zur krebsbekaempfung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OGA | New person/name/address of the applicant | ||
| OD | Request for examination | ||
| 8131 | Rejection | ||
| 8128 | New person/name/address of the agent |
Representative=s name: HENKEL, G., DR.PHIL. FEILER, L., DR.RER.NAT. HAENZ |